J. Miller

发表

Nonchimeric HLA‐Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers

J. Friedewald, M. Abecassis, M. Abecassis, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Novel therapies for chronic myelogenous leukemia.

C. Verfaillie, J. Miller, B. Jahagirdar, 2001, Experimental hematology.

Protection of cells from complement-mediated attack: CD59 receptor clustering for the entry of macromolecules into hematopoietic cells.

J. Njoroge, J. Miller, U. Wojda, 1999, Immunological investigations.

Innovative therapy for chronic myelogenous leukemia.

J. Miller, J. Miller, J. Miller, 1998, Hematology/oncology clinics of North America.

Natural Killer Cells: What Have We Learned?

J. Miller, D. Sarhan, J. Miller, 2018, Advances and Controversies in Hematopoietic Transplantation and Cell Therapy.

BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.

S. Heimfeld, C. Verfaillie, G. Dewald, 1996, Blood.

The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.

C. Verfaillie, Jeffrey S. Miller, J. Miller, 1992, Blood.

Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

J. Miller, P. Mcglave, K. Alley, 1994, Blood.

Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

J. Wagner, C. Verfaillie, S. Davies, 1995, Blood.

Expression and functional significance of an additional ligand for CTLA-4.

J. Bluestone, D. Lenschow, G. Su, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors.

W. S. Hu, Jeffrey S. Miller, J. Miller, 1996, Blood.

Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

C. Verfaillie, S. Davies, D. Weisdorf, 1996, Blood.

Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease

J. Wagner, C. June, B. Blazar, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma

D. Weisdorf, V. Bachanova, J. Miller, 2009, Bone Marrow Transplantation.

Transfusion‐associated graft‐versus‐host disease: a perspective from a cell therapy laboratory

J. Miller, D. Sumstad, D. McKenna, 2009, Transfusion.

Tolerance Versus Immunosuppression: A Perspective

G. Ciancio, J. Mathew, J. Levitsky, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.

P. N. Rao, Jeffrey S. Miller, J. Vredenburgh, 1999, Blood.

Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy.

J. Neglia, D. Arthur, Jeffrey S. Miller, 1994, Blood.

Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.

D. Weisdorf, J. Miller, T. Repka, 2000, Experimental hematology.

Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections.

F. Prósper, J. Miller, V. McCullar, 1997, Blood.

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.

R. Kratzke, G. Niehans, J. Miller, 1999, Experimental hematology.

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

J. Miller, V. Mccullar, J. Miller, 2001, Blood.

The biology of natural killer cells and implications for therapy of human disease.

E. Chiorean, J. Miller, J. Miller, 2001, Journal of hematotherapy & stem cell research.

Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells.

K. Moore, I. Lemischka, J. Miller, 1999, Blood.

Eicosanoids mediate insect nodulation responses to bacterial infections.

J. Miller, D. Stanley-Samuelson, T. Nguyen, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Autologous transplantation therapy for chronic myelogenous leukemia.

J. Miller, R. Bhatia, C. Verfaillie, 1997, Blood.

The role of autologous natural killer cells in chronic myelogenous leukemia.

J. Miller, B. Pierson, J. Miller, 1997, Leukemia & lymphoma.

Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.

C. Verfaillie, Jeffrey S. Miller, J. Miller, 1996, Blood.

CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.

J. Miller, B. Pierson, Jeffrey S. Miller, 1996, Blood.

Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium.

W. S. Hu, J. Miller, P. Mcglave, 1995, Journal of hematotherapy.

A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium.

C. Verfaillie, J. Miller, R. Bhatia, 1997, Experimental hematology.

decitabine vorinostat and haploidentical natural killer cell infusions with il 2 atimulation in high risk myelodysplastic syndrome

M. Patnaik, J. Miller, D. McKenna, 2018 .

Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma.

J. Modiano, J. Miller, J. Curtsinger, 2011, Veterinary and comparative oncology.

Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.

C. Verfaillie, J. Miller, P. Mcglave, 1991, Blood.

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

M. Linden, M. Burke, J. Miller, 2013, Bone Marrow Transplantation.

The myeloid-lymphoid initiating cell (ML-IC) assay assesses the fate of multipotent human progenitors in vitro.

K. Moore, I. Lemischka, J. Miller, 1999, Blood.

T-cell factor-1 expression during human natural killer cell development and in circulating CD56(+) bright natural killer cells.

J. Miller, T. Lund, A. Toor, 2001, Experimental hematology.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines

J. Wagner, D. Munn, B. Levine, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

CXCR4 expression in CD34+ cells and unit predominance after double umbilical cord blood transplantation

J. Wagner, C. Eide, D. Weisdorf, 2013, Leukemia.

Expansion and activation of human natural killer cells for autologous therapy.

C. Verfaillie, J. Miller, P. Mcglave, 1994, Journal of hematotherapy.

Primary bone marrow progenitors of both granulocytic and monocytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis.

J. L. Goodman, Jeffrey S. Miller, C. Nelson, 1997, The Journal of infectious diseases.

Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.

C. Verfaillie, J. Miller, P. Mcglave, 1994, Bone marrow transplantation.

Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells.

S. Cannistra, J. Griffin, J. Miller, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

J. Miller, D. Vallera, M. Gleason, 2016, Targeted Oncology.

Role of monocytes in the expansion of human activated natural killer cells.

Jeffrey S. Miller, C. Verfaillie, Jeffrey S. Miller, 1992, Blood.

Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units

J. Wagner, D. Weisdorf, J. Miller, 2009, Bone Marrow Transplantation.

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

C. Verfaillie, J. Lebkowski, D. Weisdorf, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells.

C. Verfaillie, J. Miller, 1994, Blood.

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients.

J. Wagner, Jeffrey S. Miller, D. Weisdorf, 1995, Blood.

Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.

J. Wagner, C. Verfaillie, Jeffrey S. Miller, 2001, The American journal of medicine.

Malignant neoplasms following bone marrow transplantation.

L. Robison, J. Neglia, S. Bhatia, 1996, Blood.

Soluble HLA‐G Expression and Renal Graft Acceptance

E. Carosella, P. Terasaki, J. Miller, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

C. Kalberer, E. Alici, M. Lowdell, 2015, Oncoimmunology.

Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor.

J. Miller, A. Europa, B. Pierson, 1996, Journal of hematotherapy.

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

D. Vesole, D. Weisdorf, B. Blazar, 2003, Bone Marrow Transplantation.

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

M. Linden, M. Burke, J. Miller, 2013, Bone Marrow Transplantation.

The biology of natural killer cells in cancer, infection, and pregnancy.

Jeffrey S. Miller, J. Miller, 2001, Experimental hematology.

Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.

B. Blazar, J. Miller, P. Orchard, 1997, Experimental hematology.

A novel single-cell proliferation assay shows that long-term culture-initiating cell (LTC-IC) maintenance over time results from the extensive proliferation of a small fraction of LTC-IC.

C. Verfaillie, J. Miller, Jeffrey S. Miller, 1995, Blood.

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

Jeffrey S. Miller, J. Miller, T. Repka, 1999, Experimental hematology.

Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation

J. Wagner, G. Vercellotti, D. Weisdorf, 2013, Bone Marrow Transplantation.

Phenotypic and functional characterization of committed and primitive myeloid and lymphoid hematopoietic precursors in human fetal liver.

C. Verfaillie, J. Miller, V. Roy, 1997, Experimental hematology.

Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.

C. Verfaillie, M. Steinbuch, B. Hirsch, 1998, Blood.

Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma

J. Wagner, D. Weisdorf, J. Miller, 2007, Bone Marrow Transplantation.

Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation

J. Wagner, C. Verfaillie, K. Dusenbery, 2000, Bone Marrow Transplantation.

Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.

J. Wagner, C. Verfaillie, M. Steinbuch, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

A. Skubitz, H. Wong, J. Miller, 2017, Gynecologic oncology.

Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.

J. Wagner, J. Miller, I. Vlasova-St Louis, 2021, Transplantation and cellular therapy.

Ex vivo culture of CD34+/Lin-/DR- cells in stroma-derived soluble factors, interleukin-3, and macrophage inflammatory protein-1alpha maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay.

C. Verfaillie, J. Miller, V. McCullar, 1998, Blood.

Successful autologous hematopoietic progenitor cell transplantation in a patient with an isoantibody against CD36 (glycoprotein IV, Naka)

M. Gramatzki, J. Miller, A. Humpe, 2008, Bone Marrow Transplantation.

Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation

M. Linden, A. Rashidi, J. Miller, 2018, Bone Marrow Transplantation.

Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor.

J. Moss, Jeffrey S. Miller, J. Miller, 1999, Journal of immunology.